Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers

Executive Summary

Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.

You may also be interested in...



Gilead's Trodelvy Surpasses Investors' Low Bar At ASCO, But Faces A Commercial Climb

The Phase III TROPICS-02 study in HR-positive/HER2-negative breast cancer was successful, but data for rival drug Enhertu overshadowed the results.

COVID-19 Gives US Biopharma Plenty Of Q1 Cover

Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.

Five Late-Breaking Studies To Look Out For At ASCO

Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel